Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beltavac
- Development stage
- Phase 3
- Lead developer
- Probelte Pharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**Beltavac** is a Probelte Pharma brand of subcutaneous allergen immunotherapy products comprising polymerized allergen extracts, also termed allergoids. The precise active allergen source varies by formulation; documented Beltavac programs include house dust mite extracts and grass-pollen extracts. Repeated subcutaneous administration is intended to induce allergen-specific immune tolerance and reduce symptoms of allergic rhinitis and rhinoconjunctivitis. The house dust mite formulation, containing polymerized extracts from *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, is in a Phase III study for allergic rhinitis/rhinoconjunctivitis, while a grass-pollen formulation has been studied in Phase II dose-finding trials. ([ctis.eu](https://ctis.eu/trial/2024-516893-31-01))
- Brand names
- Beltavac
- Other names
- House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinaePolymerized extract of house dust mite mixture
02
Targets
IgE (Immunoglobulin E)TCR (T cell antigen receptor complex)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on Beltavac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beltavac.